| Dr Brian P Oppermann, MD | |
|
2520 Green Tech Dr, State College, PA 16803-2308 | |
| (814) 231-4560 | |
| (814) 235-3388 |
| Full Name | Dr Brian P Oppermann |
|---|---|
| Gender | Male |
| Speciality | Rheumatology |
| Experience | 19 Years |
| Location | 2520 Green Tech Dr, State College, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194904797 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MD432589 (Pennsylvania) | Secondary |
| 207RR0500X | Internal Medicine - Rheumatology | MD432589 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Geisinger-lewistown Hospital | Lewistown, PA | Hospital |
| Geisinger Medical Center | Danville, PA | Hospital |
| Geisinger Jersey Shore Hospital | Jersey shore, PA | Hospital |
| Mount Nittany Medical Center | State college, PA | Hospital |
| Penn Highland Dubois | Dubois, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Geisinger Clinic | 5395657001 | 2866 |
News Archive
Delphi Display Systems, Inc., today announced that it has been selected to provide a turnkey digital signage solution for MedMedia Healthcare Network to be installed in the waiting rooms of doctors' offices and medical clinics located in Southern California.
Universal Detection Technology (www.udetection.com) (OTCBB: UNDT), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats, announced today that it is expanding its product catalogue to include a consumer-ready kit for the detection of black mold.
International Stem Cell Corporation, www.intlstemcell.com, announced today that the United States Patent and Trademark Office has granted ISCO patent number 7,732,202, the first of several pending patents relating to its development of human parthenogenetic Stem Cells. Human parthenogenetic stem cells are a new type of pluripotent stem cell that allows immune matching to potentially solve critical immune rejection problems, and does not involve the ethical issues that surround the use of fertilized human embryos.
Renishaw's novel drug delivery system, to be used in partnership with Herantis Pharma Plc's drug candidate CDNF for the treatment of Parkinson's disease, is about to enter phase 1-2 clinical trials. The study will be supported by a €6 million grant from Horizon 2020, the European Union's Framework Programme for Research and Innovation.
Their findings suggest that SARS-CoV-2 infection rarely occurs in daycare centers, and thus, these centers should not be considered as potential reservoirs of the virus. The study is currently available on the medRxiv* preprint server.
› Verified 5 days ago
| Entity Name | Geisinger Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366493868 PECOS PAC ID: 5395657001 Enrollment ID: O20040130000518 |
News Archive
Delphi Display Systems, Inc., today announced that it has been selected to provide a turnkey digital signage solution for MedMedia Healthcare Network to be installed in the waiting rooms of doctors' offices and medical clinics located in Southern California.
Universal Detection Technology (www.udetection.com) (OTCBB: UNDT), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats, announced today that it is expanding its product catalogue to include a consumer-ready kit for the detection of black mold.
International Stem Cell Corporation, www.intlstemcell.com, announced today that the United States Patent and Trademark Office has granted ISCO patent number 7,732,202, the first of several pending patents relating to its development of human parthenogenetic Stem Cells. Human parthenogenetic stem cells are a new type of pluripotent stem cell that allows immune matching to potentially solve critical immune rejection problems, and does not involve the ethical issues that surround the use of fertilized human embryos.
Renishaw's novel drug delivery system, to be used in partnership with Herantis Pharma Plc's drug candidate CDNF for the treatment of Parkinson's disease, is about to enter phase 1-2 clinical trials. The study will be supported by a €6 million grant from Horizon 2020, the European Union's Framework Programme for Research and Innovation.
Their findings suggest that SARS-CoV-2 infection rarely occurs in daycare centers, and thus, these centers should not be considered as potential reservoirs of the virus. The study is currently available on the medRxiv* preprint server.
› Verified 5 days ago
| Entity Name | Geisinger-hm Joint Venture Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144876137 PECOS PAC ID: 1355676370 Enrollment ID: O20190826000803 |
News Archive
Delphi Display Systems, Inc., today announced that it has been selected to provide a turnkey digital signage solution for MedMedia Healthcare Network to be installed in the waiting rooms of doctors' offices and medical clinics located in Southern California.
Universal Detection Technology (www.udetection.com) (OTCBB: UNDT), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats, announced today that it is expanding its product catalogue to include a consumer-ready kit for the detection of black mold.
International Stem Cell Corporation, www.intlstemcell.com, announced today that the United States Patent and Trademark Office has granted ISCO patent number 7,732,202, the first of several pending patents relating to its development of human parthenogenetic Stem Cells. Human parthenogenetic stem cells are a new type of pluripotent stem cell that allows immune matching to potentially solve critical immune rejection problems, and does not involve the ethical issues that surround the use of fertilized human embryos.
Renishaw's novel drug delivery system, to be used in partnership with Herantis Pharma Plc's drug candidate CDNF for the treatment of Parkinson's disease, is about to enter phase 1-2 clinical trials. The study will be supported by a €6 million grant from Horizon 2020, the European Union's Framework Programme for Research and Innovation.
Their findings suggest that SARS-CoV-2 infection rarely occurs in daycare centers, and thus, these centers should not be considered as potential reservoirs of the virus. The study is currently available on the medRxiv* preprint server.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brian P Oppermann, MD 100 N Academy Ave, Danville, PA 17822-3034 Ph: (570) 271-6144 | Dr Brian P Oppermann, MD 2520 Green Tech Dr, State College, PA 16803-2308 Ph: (814) 231-4560 |
News Archive
Delphi Display Systems, Inc., today announced that it has been selected to provide a turnkey digital signage solution for MedMedia Healthcare Network to be installed in the waiting rooms of doctors' offices and medical clinics located in Southern California.
Universal Detection Technology (www.udetection.com) (OTCBB: UNDT), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats, announced today that it is expanding its product catalogue to include a consumer-ready kit for the detection of black mold.
International Stem Cell Corporation, www.intlstemcell.com, announced today that the United States Patent and Trademark Office has granted ISCO patent number 7,732,202, the first of several pending patents relating to its development of human parthenogenetic Stem Cells. Human parthenogenetic stem cells are a new type of pluripotent stem cell that allows immune matching to potentially solve critical immune rejection problems, and does not involve the ethical issues that surround the use of fertilized human embryos.
Renishaw's novel drug delivery system, to be used in partnership with Herantis Pharma Plc's drug candidate CDNF for the treatment of Parkinson's disease, is about to enter phase 1-2 clinical trials. The study will be supported by a €6 million grant from Horizon 2020, the European Union's Framework Programme for Research and Innovation.
Their findings suggest that SARS-CoV-2 infection rarely occurs in daycare centers, and thus, these centers should not be considered as potential reservoirs of the virus. The study is currently available on the medRxiv* preprint server.
› Verified 5 days ago
Paul Andrew Koberna, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2134 Sandy Dr Ste 16, State College, PA 16803 Phone: 814-272-5805 Fax: 814-272-0110 | |
Peter F. Pepe, M.D. Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 1850 E Park Ave, Suite 201, State College, PA 16803 Phone: 814-234-8800 | |
Keriann Nickola Gray, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 200 Scenery Dr., State College, PA 16801 Phone: 814-231-4560 Fax: 814-231-6246 | |
Dr. Manisha N. Patel, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 200 Scenery Dr, State College, PA 16801 Phone: 814-231-4560 Fax: 814-231-6246 | |
Dr. Joel B Haight, M.D. Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 32 Colonnade Way, State College, PA 16803 Phone: 814-272-4445 Fax: 814-272-4450 | |
Jeffrey W. Pro, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1850 E Park Ave, Suite 302, State College, PA 16803 Phone: 814-278-4680 Fax: 814-235-1523 | |
Dr. Scott A. Sulman, D.O. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 200 Scenery Dr, State College, PA 16801 Phone: 814-231-4560 Fax: 814-235-5512 |